Page 178 - Haematologica May 2020
P. 178

A. Lazaryan et al.
Prognostic impact of cytogenetic abnormali-
ties in adult patients with Philadelphia-chro- mosome (Ph)-negative acute lymphoblastic leukemia (ALL) who underwent allogeneic stem cell transplant (allo-SCT). Blood. 2015;126(23):2024.
4. Lafage-Pochitaloff M, Baranger L, Hunault M, et al. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood. 2017;130(16):1832-1844.
5. Shaffer L, McGowan J, Schmid M. ISCN 2013: An International System for Human Cytogenetic Nomenclature. Basel. S Krager AG, 2012.
6. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic fac- tor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189-3197.
7. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lym- phoblastic leukemia. Blood. 2010;115(2): 206- 214.
8. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111(5):2563- 2572.
9. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of min- imal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153-4162.
10. Zhang X, Zhang MJ. SAS macros for estima- tion of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed. 2011;101(1):87-93.
11. Zhang X, Loberiza FR, Klein JP, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed. 2007;88(2):95-101.
12. Paulsson K, Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2009;48(8): 637-660.
13. Hakeem A, Shiekh AA, Bhat GM, Lone AR. Prognostification of ALL by cytogenetics. Indian J Hematol Blood Transfus. 2015;31 (3):322-331.
14. Breems DA, Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spec- trum. Haematologica. 2011;96(4):491-493.
15. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
16. Motllo C, Ribera JM, Morgades M, et al. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer. 2014;120(24):3958-3964.
17. Kenderian SS, Al-Kali A, Gangat N, et al. Monosomal karyotype in Philadelphia chro- mosome-negative acute lymphoblastic leukemia. Blood Cancer J. 2013;3(7):e122.
22. Kubo Y, Kakazu N, Tasaka T, et al. Acute lymphoblastic leukemia (ALL) with t(8;14)(q11.2;q32) in an elderly patient. Leuk Res. 2010;34(3):e82-84.
23. Dyer MJ, Akasaka T, Capasso M, et al. Immunoglobulin heavy chain locus chromo- somal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers? Blood. 2010;115(8): 1490-1499.
24. Liu W, Hu S, Konopleva M, et al. De novo MYC and BCL2 double-hit B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in pediatric and young adult patients associated with poor prognosis. Pediatr Hematol Oncol. 2015;32(8):535-547.
25. Russell LJ, Enshaei A, Jones L, et al. IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor out- come. J Clin Oncol. 2014;32(14):1453-1462.
26. Herold T, Schneider S, Metzeler KH, et al. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, per- sistence of minimal residual disease and poor prognosis. Haematologica. 2017;102 (1):130-
   18. Esteve J, Labopin M, Czerw T, et al.
Allogeneic hematopoietic cell transplanta-
tion (alloHCT) for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 (MLL/AF4)
B-acute lymphoblastic leukemia in first 138.
complete remission (CR1): favorable out- come of patients with negative minimal residual disease (MRD) status at trans- plant. a report from the Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation (ALWP-EBMT). Blood. 2017;130(Suppl 1):669.
27. Issa GC, Kantarjian HM, Yin CC, et al. Prognostic impact of pretreatment cytogenet- ics in adult Philadelphia chromosome-nega- tive acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017;123(3):459-467.
28. Iacobucci I, Iraci N, Messina M, et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B- cell acute lymphoblastic leukemia. PloS one. 2012;7(7):e40934.
29. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblas- tic leukemia. N Engl J Med. 2009;360(5):470-
19. Marks DI, Moorman AV, Chilton L, et al. The
clinical characteristics, therapy and outcome
of 85 adults with acute lymphoblastic
leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica. 2013;98(6):945-952. 480.
20. Moore S, Suttle J, Bain S, Story C, Rice M. Acute lymphoblastic leukemia characterized by t(8;14)(q11.2;q32). Cancer Genet Cytogenet. 2003;141(1):1-4.
21. Messinger YH, Higgins RR, Devidas M, Hunger SP, Carroll AJ, Heerema NA. Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study. Cancer Genet. 2012;205(9):453-458.
30. Dupuis A, Gaub MP, Legrain M, et al. Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia. 2013;27(2):503-507.
31. Moorman AV, Hagemeijer A, Charrin C, Rieder H, Secker-Walker LM. The transloca- tions, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. European 11q23 Workshop participants. Leukemia. 1998; 12(5):805-810.
 1338
  haematologica | 2020; 105(5)
   


























































   176   177   178   179   180